Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer (NCT07226999)
A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
🩺 Plain-English Summary (8th-Grade Level)
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread widely in the body. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have extensive-stage small cell lung cancer confirmed by lab tests. * Have not received chemotherapy or radiation for this type of lung cancer. * Be in good physical condition and have healthy organs based on medical tests. The study has two parts: * In the first part, researchers will check how safe the study medicine is and how well people tolerate it when given with chemotherapy. * In the second part, they will compare study medicine plus chemotherapy to another approved treatment (atezolizumab plus chemotherapy) to see which works better. Participants will receive the treatment through IV infusions (medicine given directly into a vein). The treatment will be given in repeated time periods called cycles. Some participants will continue receiving the study medicine alone after the initial treatment.
Who can join: Review the eligibility criteria below.
Location: Highlands Oncology Group — Fayetteville, Arkansas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (83 Sites)
Showing the first 25 of 83 sites.
- Highlands Oncology Group — Fayetteville, Arkansas
- Highlands Oncology Group — Rogers, Arkansas
- Highlands Oncology Group — Springdale, Arkansas
- BRCR Coral Springs — Coral Springs, Florida
- Mid Florida Hematology and Oncology Center — Orange City, Florida
- BRCR Global - Tamarac — Tamarac, Florida
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Texas Oncology - Northeast Texas — Allen, Texas
- Texas Oncology - DFW — Arlington, Texas
- Texas Oncology - DFW — Arlington, Texas
- Texas Oncology - Gulf Coast — Beaumont, Texas
- Texas Oncology - DFW — Bedford, Texas
- Texas Oncology - DFW — Dallas, Texas
- Texas Oncology - DFW — Dallas, Texas
- Texas Oncology - DFW — Dallas, Texas
- Texas Oncology - DFW — Dallas, Texas
- Texas Oncology - DFW — Dallas, Texas
- Texas Oncology - Northeast Texas — Denison, Texas
- Texas Oncology - Northeast Texas — Denton, Texas
- Texas Oncology - Northeast Texas — Flower Mound, Texas
- Texas Oncology - DFW — Fort Worth, Texas
- Texas Oncology - San Antonio — Fredericksburg, Texas
- Texas Oncology - DFW — Grapevine, Texas
- Texas Oncology - Gulf Coast — Houston, Texas
- Texas Oncology - Gulf Coast — Houston, Texas
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Small Cell Lung Cancer (SCLC)
- Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer — Mobile, Alabama
- A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC — Los Angeles, California
- Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer — Chicago, Illinois
- A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) — Duarte, California
- DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy — Mobile, Alabama
Explore by condition: All Small Cell Lung Cancer (SCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.